CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 81 enrolled
Drug / intervention
MLN2480 +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02327169
NCT02327169Phase 1Completed
CompareCT.gov

A Multiarm, Open-label, Phase 1b Study of MLN2480 (an Oral A-, B-, and CRAF Inhibitor) in Combination With MLN0128 (an Oral mTORC 1/2 Inhibitor), or Alisertib (an Oral Aurora A Kinase Inhibitor), or Paclitaxel, or Cetuximab, or Irinotecan, in Adult Patients With Advanced Nonhematologic Malignancies

Millennium Pharmaceuticals, Inc.·interventional·Posted Dec 30, 2014·Updated Feb 25, 2020

In Brief

A Phase 1 clinical trial evaluating MLN2480, MLN0128, and 4 other interventions for Advanced Nonhematologic Malignancies. Completed, enrolled 81 participants across 14 sites in 4 countries.

Detailed Summary

The primary purpose of this study is to determine the safety profile and the maximum tolerated doses (MTDs)/ potential recommended phase 2 doses (RP2Ds) of the combination treatments of MLN2480 + MLN0128, MLN2480 + alisertib, MLN2480 + paclitaxel, MLN2480 + cetuximab, and MLN2480 + irinotecan in participants with advanced nonhematologic malignancies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Nonhematologic Malignancies
CountriesFrance, Spain, United Kingdom, United States
Collaborators--

Timeline

Phase 1CompletedFinished
201520162017201820192020202120222023202420252026
First PostedDec 30, 2014
Enrollment StartJan 14, 2015
Primary CompletionJul 2, 2018
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 11.5 years ago

Interventions

MLN2480drug

MLN2480 tablets.

MLN0128drug

MLN0128 capsules.

Alisertibdrug

Alisertib tablets.

Paclitaxeldrug

Paclitaxel IV infusion.

Cetuximabdrug

Cetuximab IV infusion.

Irinotecandrug

Irinotecan IV infusion.